Search

Molecular cavities formed by π‐conjugated component(s) generally, tend to collapse in the absence of guest molecule(s) especially in the solution‐state, because of strong π•••π interactions between molecular components. Recently, we have explored the importance of mutual induced‐fit effect to sort out this issue. In the present report, we have shown the role of substituents on the effectiveness of mutual induced‐fit process in an artificial system. [ABSTRACT FROM AUTHOR]

Context. High-redshift radio(-loud) galaxies (HzRGs) are massive galaxies with powerful radio-loud active galactic nuclei (AGNs) and serve as beacons for protocluster identification. However, the interplay between HzRGs and the large-scale environment remains unclear. Aims. To understand the connection between HzRGs and the surrounding obscured star formation, we investigated the overdensity and spatial distribution of submillimeter-bright galaxies (SMGs) in the field of 4C 23.56, a well-known HzRG at z = 2.48. Methods. We used SCUBA-2 data (σ ∼ 0.6 mJy) to estimate the 850 μm source number counts and examine the radial and azimuthal overdensities of the 850 μm sources in the vicinity of the HzRG. Results. The angular distribution of SMGs is inhomogeneous around the HzRG 4C 23.56, with fewer sources oriented along the radio jet. We also find a significant overdensity of bright SMGs (S​850 μm ≥ 5 mJy). Faint and bright SMGs exhibit different spatial distributions. The former are concentrated in the core region, while the latter prefer the outskirts of the HzRG field. High-resolution observations show that the seven brightest SMGs in our sample are intrinsically bright, suggesting that the overdensity of bright SMGs is less likely due to the source multiplicity. [ABSTRACT FROM AUTHOR]

BACKGROUND One of the major determinants of exercise intolerance and limiting symptoms among patients with obstructive hypertrophic cardiomyopathy (HCM) is an elevated intracardiac pressure resulting from left ventricular outflow tract obstruction. Aficamten is an oral selective cardiac myosin inhibitor that reduces left ventricular outflow tract gradients by mitigating cardiac hypercontractility. METHODS In this phase 3, double-blind trial, we randomly assigned adults with symptomatic obstructive HCM to receive aficamten (starting dose, 5 mg; maximum dose, 20 mg) or placebo for 24 weeks, with dose adjustment based on echocardiography results. The primary end point was the change from baseline to week 24 in the peak oxygen uptake as assessed by cardiopulmonary exercise testing. The 10 prespecified secondary end points (tested hierarchically) were change in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS), improvement in the New York Heart Association (NYHA) functional class, change in the pressure gradient after the Valsalva maneuver, occurrence of a gradient of less than 30 mm Hg after the Valsalva maneuver, and duration of eligibility for septal reduction therapy (all assessed at week 24); change in the KCCQ-CSS, improvement in the NYHA functional class, change in the pressure gradient after the Valsalva maneuver, and occurrence of a gradient of less than 30 mm Hg after the Valsalva maneuver (all assessed at week 12); and change in the total workload as assessed by cardiopulmonary exercise testing at week 24. RESULTS A total of 282 patients underwent randomization: 142 to the aficamten group and 140 to the placebo group. The mean age was 59.1 years, 59.2% were men, the baseline mean resting left ventricular outflow tract gradient was 55.1 mm Hg, and the baseline mean left ventricular ejection fraction was 74.8%. At 24 weeks, the mean change in the peak oxygen uptake was 1.8 ml per kilogram per minute (95% confidence interval [CI], 1.2 to 2.3) in the aficamten group and 0.0 ml per kilogram per minute (95% CI, -0.5 to 0.5) in the placebo group (least-squares mean between-group difference, 1.7 ml per kilogram per minute; 95% CI, 1.0 to 2.4; P<0.001). The results for all 10 secondary end points were significantly improved with aficamten as compared with placebo. The incidence of adverse events appeared to be similar in the two groups. CONCLUSIONS Among patients with symptomatic obstructive HCM, treatment with aficamten resulted in a significantly greater improvement in peak oxygen uptake than placebo. (Funded by Cytokinetics; SEQUOIA-HCM ClinicalTrials.gov number, NCT05186818.) [ABSTRACT FROM AUTHOR]